Prelude Therapeutics Incorporated
PRLDPrelude Therapeutics Incorporated is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company specializes in designing small molecule inhibitors to treat various cancers, leveraging innovative precision medicine approaches to improve patient outcomes.
Company News
Prelude Therapeutics presented preclinical data on two promising therapeutic approaches for myeloproliferative neoplasms (MPNs): a JAK2V617F-selective JH2 inhibitor (PRT12396) and a mutant calreticulin targeted degrader antibody conjugate, demonstrating potential disease-modifying capabilities.
Prelude Therapeutics reported a Q2 2025 net loss of $31.2 million, reduced operating expenses, and focused on its oral SMARCA2 degrader program while maintaining cash reserves to fund operations into Q2 2026.
S, ASAN, PRLD, EMKR and SNAP have been added to the Zacks Rank #1 (Strong Buy) List on January 25, 2023.
Morgan Stanley downgraded its rating of Prelude Therapeutics (NASDAQ:PRLD) to Underweight with a price target of $4.00, changing its price target from $10.00 to $4.00. Shares of Prelude Therapeutics are trading up 0.0% over the last 24 hours, at $4.37 per share. A move to $4.00 would account for a 8.47% decrease from the current share price. Abou...
